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Abstract
Introduction Quantitative proteomics using tandem mass
spectrometry is an attractive approach for identification of
potential cancer biomarkers. Fractionation of complex
tissue samples into subproteomes prior to mass spectromet-
ric analyses increases the likelihood of identifying cancer-
specific proteins that might be present in low abundance. In
this regard, glycosylated proteins are an interesting class of
proteins that are already established as biomarkers for
several cancers.
Materials and Methods In this study, we carried out
proteomic profiling of tumor and adjacent non-cancer liver
tissues from hepatocellular carcinoma (HCC) patients.
Glycoprotein enrichment from liver samples using lectin
affinity chromatography and subsequent 18O/16O labeling
of peptides allowed us to obtain relative abundance levels
of lectin-bound proteins. As a complementary approach, we
also examined the relative expression of proteins in HCC
without glycoprotein enrichment. Lectin affinity enrichment
was found to be advantageous to quantitate several
interesting proteins, which were not detected in the whole
proteome screening approach. We identified and quantitated
over 200 proteins from the lectin-based approach. Interest-
ing among these were fetuin, cysteine-rich protein 1, serpin
peptidase inhibitor, leucine-rich alpha-2-glycoprotein 1,
melanoma cell adhesion molecule, and heparan sulfate
proteoglycan-2. Using lectin affinity followed by PNGase F
digestion coupled to 18O labeling, we identified 34
glycosylation sites with consensus sequence N-X-T/S.
Western blotting and immunohistochemical staining were
carried out for several proteins to confirm mass spectrom-
etry results.
Conclusion This study indicates that quantitative proteomic
profiling of tumor tissue versus non-cancerous tissue is a
promising approach for the identification of potential
biomarkers for HCC.
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Introduction
The incidence of hepatocellular carcinoma is rising, making
it the fifth most common malignancy worldwide [1]. This
increased incidence is attributed to viral hepatitis and
carcinogenic toxins such as aflatoxin [2]. Alpha fetoprotein
(AFP), one of the tumor markers used for diagnostic
purposes in hepatocellular carcinoma (HCC), is limited in
its diagnostic utility because 50% (35% in Johns Hopkins
Hospital [3]) of the patients with HCC do not show high
level of AFP [4–6]. Serum level of des-gamma-carboxy
prothrombin (DCP) is also shown to be useful for the
diagnosis of HCC in conjunction with AFP [7]. Several
studies have reported potential diagnostic markers for HCC,
which are associated with chromosomal alterations, mRNA
expression alterations, protein-level alterations and post-
translational modifications. Lately, proteomic strategies
have been extensively used for biomarker discovery
because of their ability for multiplex analysis using
quantitative approaches. Quantitative proteomics using
isotope-labeling techniques provide opportunities to ana-
lyze changes in protein levels in multiple samples in an
unbiased fashion [8]. However, a limitation of these
techniques is that, due to the complexity of samples, least
abundant proteins are not detected.
O- and N-glycosylation of proteins have been associated
with cancers including HCC. For example, an overall
increase in fucosylation has been reported in HCC serum
proteins [9]. Increased or altered glycosylation is also
reported to be associated with secreted alpha fetoprotein
[10] and transferrin [11] in HCC. Glycomic profiling is a
complementary strategy used to identify cancer-specific
glycans especially in ovarian cancer [12], HCC [13], and
pancreatic cancer [14]. There are several reports on the
application of lectin-based enrichment method to study the
glycoproteome in cancers [15, 16]. Lectin reactive form of
AFP is reported to be a more sensitive marker for HCC
[17]. The profile of carbohydrate moieties of glycoproteins
has also been used for differentiating normal from
cancerous tissue in lung [16] and pancreatic cancers [18].
Since individual lectins have their own specificity while the
nature of the carbohydrates present in samples may vary
dramatically, it is advantageous to use a combination of
lectins for enrichment purposes. Such a multiple lectin
affinity approach has been used for breast cancer biomarker
analysis [19]. A mixture of different lectins has also been
used for lectin affinity enrichment method to identify
biomarkers in bile secretome from cancer patients [20].
Stable isotope can be incorporated into proteins and
peptides by different methods in vitro such as ICAT [21],
iTRAQ [22], 18O-labeling methods [23], and in vivo
labeling, using heavy-isotope-labeled amino acids in cell
culture (SILAC) [24]. Labeling of peptides in the presence
of 18O-labeled water is a simple method without chemical
tagging and can be readily used to analyze the proteins
separated by SDS-PAGE [25]. The present study is
designed to analyze subproteome in HCC using affinity
enrichment and relative quantitation based on 18O labeling.
Further, analysis of glycopeptides treated with PNGase F
provides definitive evidence of N-linked glycosylation [20].
Western blotting was used to confirm the differential
expression results obtained by quantitative mass spectrom-
etry. The candidate biomarkers were screened by immuno-
histochemical labeling using tissue microarrays containing
hepatocellular carcinoma and non-cancerous liver tissue.
We validated fetuin, a glycoprotein involved in endocytosis
using immunohistochemical labeling. We also identified N-
glycosylated peptides with sites from lectin-enriched
protein. These results demonstrate advantages of lectin
affinity enrichment method before quantitative proteomics




Liver tissue samples were obtained after obtaining appropri-
ate Institutional Review Board approval. One pair of tumor
tissue and patient-matched non-cancerous tissue was col-
lected at the time of surgery from patients and snap-frozen in
liquid nitrogen. Serum samples were collected from HCC
patients and stored at −80°C until analysis. A total of 114
HCC samples and 79 non-cancer liver sections from two
tissue microarrays were used in this study. Formalin fixed
and paraffin embedded tissue microarrays (Creative Biolabs,
Cat No. CBL-TMA-070 and CBL-TMA-076), which con-
sisted of 55 tissue sections from hepatocellular carcinoma
with I, II, and III stages and 20 non-cancer tissues were used
for immunohistochemical labeling. Tissue microarrays
obtained from Imgenex consisted of 59 tumors (13 meta-
static tissues, 46 poor to well-differentiated HCC, Cat. No.
IMH-318) and 59 non-cancer tissues (Cat. No. IMH-342).
Frozen tissues were used for mass spectrometric analysis and
validation by Western blotting.
Lectin Affinity Enrichment
Tissue lysates were prepared from fresh frozen tissues from
the tumor and adjacent non-cancerous region from a patient
diagnosed with HCC in the presence of cocktail protease
inhibitor and 10 mM phosphate buffer pH 7.8 (wash
buffer). Lysates (4 mg protein) were subsequently incubat-
ed with 100 μl of each of ConA sepharose (Amersham
BioSciences), wheat germ agglutinin and jacalin agarose for
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12 h at 4°C. The beads were then washed three times using
wash buffer and the bound proteins eluted using a mixture of
carbohydrates (100 mM each of N-acetylglucosamine, meli-
biose, and galactose). The eluate was dialyzed against wash
buffer (three volumes) to remove free sugars, concentrated
and resolved by SDS-PAGE and visualized using Colloidal
Coomassie staining.
Serum samples were obtained from patients diagnosed
with hepatocellular carcinoma. Pooled normal serum was
obtained from Invitrogen. Serum samples were prepared by
incubating 100 μl (7 mg) of serum with 0.5 ml of mixture
of lectins (ConA sepharose, jacalin, wheat germ lectins)
overnight at 4°C in Tris-buffered saline (0.05 M Tris–HCL,
pH 7.1, 0.15 M NaCl). Beads were washed three times in
Tris buffer saline and boiled in Laemmli buffer for 10 min
at 95°C to elute the proteins, and eluted proteins were run
on 10% SDS-PAGE for further analysis by Western blot.
18O Labeling and In-gel Trypsin Digestion
Liver tissue samples from non-cancer and HCC tissues were
run in parallel lanes on an SDS-PAGE gel for comparative
analysis. Two gels were used for analysis, one from whole
proteome and another from lectin-enriched proteins from
HCC and normal tissues. Exact size gel slices corresponding
to individual protein bands from HCC and normal tissues
were excised and used for in-gel trypsin digestion as
explained earlier [11] using Stratagene prolytica 18O
labeling kit. In brief, sliced colloidal Coomassie-stained
gel bands were destained and completely dehydrated gel
slices were incubated with trypsin in the presence of heavy
or normal water overnight. After completion of digestion,
peptides were extracted from each sample, dried and
subjected to post-trypsin digestion. Samples were incubated
with immobilized trypsin (5 μl beads per sample) in the
presence of heavy or normal water for 3 h. Finally, peptides
derived from adjacent bands corresponding to normal and
HCC were acidified, mixed, and analyzed on a quadrupole
time-of-fight (QToF) mass spectrometer.
PNGase F Treatment for Identification
of N-glycosylation Sites
Lectin affinity enriched proteins from HCC tissue were
separated on 1D SDS-PAGE and stained with colloidal
Coomassie. Protein bands were destained, reduced, and
alkylated. Gel pieces were then subjected to in-gel trypsin
(Promega) digestion and extracted peptides were dried
completely. For the confirmation of N-glycosylation sites,
peptides were incubated with PNGase F in the presence of
18O-water at 37°C for 3 h. After incubation, peptides were
analyzed by LC-MS/MS (liquid chromatography–tandem
mass spectrometry).
LC-MS/MS Analysis and Quantitation
In a separate study HCC and normal whole tissue lysates
were analyzed on a SDS-PAGE gel and 18O labeling was
done during in-gel trypsin digestion. For the common
proteins found in this experiment, we were able to compare
the changes in ratios to study glycoyslation status of
proteins in normal and HCC. Bands were destained using
ammonium bicarbonate in 50% ACN, dehydrated by
acetonitrile and dried completely. Digestion was carried
out in sequence grade trypsin (Promega, Southampton,
UK), 20 μg/ml in 16O-water or 18O-water. Peptides were
extracted using 16O-water or 18O-water three times and
dried in SpeedVac. Subsequently, postdigest-end labeling
was carried using prewashed immobilized trypsin (Strata-
gene; 2 μl/sample). Immobilized trypsin was added to the
dried peptide samples and subsequently reconstituted in
8 μl of 18O-water or 16O-water, 2 μl of acetonitrile and
incubated for 4 h at room temperature. Samples were
centrifuged 10,000 ×g to remove the immobilized trypsin.
Supernatant was acidified with 1 μl formic acid and stored
at −80°C until LC-MS/MS analysis.
For LC-MS/MS analysis, peptides from paired samples
were mixed and analyzed using Micromass quadrupole time-
of-flight mass spectrometer (QToF) connected to reversed-
phase nano LC system (Agilent 1100). The trap column
consisted of (150 μM×3 cm, C18, 15 μm, 300A, YDAC,
flow rate 1.5 μl/min) and analytical column (75 μM×10 cm,
C18, 5 μm, 300A, YDAC, flow rate 200 nl/min), solvent
system included 0.4% acetic acid, 0.004% heptafluorobutyric
acid). The peptides were eluted using a gradient of acetonitrile
up to 45% containing 0.4% acetic acid, 0.004% heptafluor-
obutyric acid. LC-MS/MS analysis was based on data
dependent analysis (DDA) manner, performed using a 1-s
MS survey scan m/z, 300-1,800 followed by four MS/MS
scans (m/z, 50–1,800) for most intense ions and precursor
ions were excluded for 60 s for the next MS/MS scans. A total
of 4.4 s time was allowed for MS/MS spectrum acquisition.
The identification and quantitation of the peptide was
done after formatting the mass spectrometry data. LC-MS/
MS data acquired using Masslynx (Micromass) were
searched using Mascot (Matrixscience, Manchester, UK).
While searching the database, 18O at C-terminal carboxyl
group (+4 Da) and oxidation of methionine were allowed as
variable modification. Relative abundance of proteins was
quantitated using MSQuant software downloaded from
http://msquant.sourceforge.net [26] and expressed as fold
changes (±S.D.). Essentially, Mascot search results were
parsed with LC-MS/MS instrument data file using
MSQuant. The new_MSQ_quantitationModes.xml files
were modified to read the mascot output files and identify
the correct light and heavy isotopic MS peaks. The
quantitation data was also verified by manual inspection
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of heavy- and light-peptide-derived MS and MS/MS
spectra in MSQuant.
Western Blot
Validation of the mass spectrometry results was carried out
for a subset of proteins by Western blotting analysis using
specific antibodies. These proteins were selected based on
their functional relevance and differential expression be-
tween the cancerous and normal liver tissue. Eighty
micrograms of protein was resolved on SDS-PAGE and
transferred electrophoretically onto a nitrocellulose mem-
brane. The membrane was blocked using 5% bovine serum
albumin prepared in phosphate-buffered saline containing
0.1% Tween 20 (PBS-T) for 1 h at room temperature. The
membrane was probed with specific primary antibody for 3 h
and washed thrice with PBS-T and incubated in the HRP-
conjugated secondary antibody for 1 h. After the incubation,
the membrane was washed thrice in PBS-T. The signal was
visualized by an enhanced chemiluminescence solution and
exposed to Hyperfilm. Following antibodies were used for
Western blot analysis. Fetuin (AF 1184, 1:1000, R&D
systems) and CSRP1 (SC-33331, 1:1000, Santa Cruz).
Immunohistochemical Labeling
Immunohistochemical labeling was performed on liver
tissue sections and liver cancer tissue microarrays for a
subset of proteins based on their biological relevance.
Tissue microarrays were obtained from Creative Biolabs,
NY (tumor TMA, CBL-TMA-070 and normal TMA, CBL-
TMA-076) and Imgenex, San Diego, CA (tumor TMA,
IMH 318, lot CS3 and normal TMA, IMH-342 lot CSN3).
The Envision kit (DAKO) was used according to the
manufacturer’s specifications. Briefly, the slides were first
deparaffinized by xylene and rehydrated with ethanol.
Antigen retrieval was done by heating the slides in
0.01 mol/L of sodium citrate buffer for 20 min on a
steamer. After blocking by peroxidase, the sections were
incubated with primary antibody anti-Fetuin A (dilution
1:400). After rinsing with wash buffer, the slides were
incubated with HRP-conjugated appropriate secondary
antibody. The signal was developed using chromogen
supplied for peroxidase. Tissue sections were observed
using Nikon DS-Fi1, microscope-operated using NIS-
Elements F package. The immunostaining was assessed
by an experienced liver pathologist and intensity was
scored as negative, weak (1+), moderate (2+), and strong
(3+). The distribution of staining of cancer cells was
scored as 3+ for maximum distribution and, accordingly,
2+ and 1+ score was given for lower distribution. The
following antibodies were used for immunohistochemical
analysis: Fetuin (1:100) and CSRP1 (1:100).
Results and Discussion
The strategy used for quantitative profiling of lectin binding
proteins from HCC liver tissue is shown in scheme Fig. 1.
Recently, mass-spectrometry-based relative quantitation
approach has been used to quantitate peptides containing
N-linked glycosylation and also to identify the site of
glycosylation [27]. Our approach of lectin affinity enrich-
ment followed by 18O-labeling strategy was aimed at
identifying proteins undergoing both N- and O-linked
modifications in which the mass-spectrometry-based quan-
titation is based on any peptide derived from lectin-bound
proteins and not glycopeptides alone. A mixture of lectins
was used for enrichment of a broader group of glycopro-
Fig. 1 Strategy used for the enrichment of glycosylated proteins for
16O/18O labeling based quantitative mass spectrometric analysis of
liver proteins in HCC. Tissue lysates (4 mg) were prepared from
tumor and non-tumor liver tissues from a diagnosed case of HCC and
incubated with mixture of lectins. The lectin-bound proteins were
eluted using mixture of sugars and bound proteins derived from tumor
and non-tumor samples were resolved separated on SDS-PAGE. In-gel
trypsin digestion was carried out in the presence of 16O/18O-water
differential labeling of peptides derived from non-tumor/tumor
samples. After mixing the labeled and unlabeled peptides, the LC-
MS/MS analysis was done using quadrupole time-of-flight mass
spectrometer
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teins in samples from normal individual and HCC patients.
16O/18O labeling allows quantitative profiling of a pair of
samples and it relies on 18O labeling of peptides at C-
terminal carboxyl groups during trypsin digestion in the
presence of heavy water, which allows relative quantitation
using mass spectrometry. Interesting candidate proteins
found in this study were validated using tissue microarrays.
Peptides containing N-linked glycosylation sites were
identified by enzymatic incorporation 18O at the sites of
glycosylation.
Lectin Affinity Chromatography for Enrichment
of Glycoproteins
It has been established that aberrant glycosylation serves as
a marker of tumor progression in cancers. Several reagents
that block glycosylation have been shown to inhibit tumor
metastasis. N- or O-glycosylation of membrane components
play an important role in altering tumor cell adhesion or
motility [28]. In general, glycosylation modification is
involved in cell adhesion, enhanced matrix destructive
properties and cell motility in tumors.
Lectins are proteins that bind carbohydrates and can be
used to enrich glycoproteins. Lectins can be distinguished
based on their carbohydrate specificity. Different lectins can
be used for isolation of specific glycosylated proteins from
a complex sample. Concanavalin A preferentially binds
alpha-mannosyl groups, wheat germ agglutinin has a higher
specificity for N-acetylglucosamine-containing glycopro-
teins and jacalin interacts readily with mannose, glucose,
and N-acetylneuraminic acid. Since these lectins show
affinity for a broad spectrum of glycoproteins, we used
the mixture of the above lectins and glycoproteins eluted
using corresponding mixture of sugars. In our study, we
were able to capture several proteins by lectin affinity
purification which were not detected in unfractionated
samples, which include transforming growth factor, beta-
induced, 68 kDa, apolipoprotein A-1, destrin, and trans-
gelin (Table 1). A complete list of overexpressed proteins is
given in Supplementary Table 1.
18O Labeling and Mass Spectrometry
Differential labeling of peptides by 18O labeling using
trypsin has been shown to be a simple and efficient method
of relative quantitation of proteins [20, 29]. We used 18O-
labeling method of quantitation for proteins obtained from
tissue lysates using lectin-bound beads. Peptides derived
from HCC tissue and non-cancerous tissue were labeled
with heavy and light oxygen, respectively. After mixing,
the peptides were analyzed using LC-MS/MS on a
quadrupole time-of-flight mass spectrometer. 18O/16O-
labeled peptides appear as doublets in MS, and ratio of
peak intensities indicates relative differences in level of
protein expression. Labeling at both oxygen atoms from the
C-terminal carboxyl group is confirmed by visual inspec-
tion of spectrum. MSQuant assigned monoisotopic peaks
from 16O-labeled and two 18O-labeled peptides. Corrections
to the fold changes applied when there is a mixed labeling
[30]. Peptide ratios were grouped and the average value is
taken as protein-level fold changes. With a cutoff of
threefold, we found 30 proteins to be overexpressed in
HCC (Table 2).
Overexpressed Proteins in HCC
We used the 18O-labeling method for the relative quantita-
tion of proteins from HCC and adjacent normal tissue. Both
unfractionated sample and eluates of lectin-bound proteins
from HCC and adjacent normal were separated on 1D SDS-
PAGE. Nearly 50% of the proteins identified from lectin
affinity methods were also found in whole proteome
analysis allowing the comparison of glycosylation status
of these proteins in cancer. Both quantitation approaches
revealed many known and novel upregulated proteins in
cancer. Table 1 shows a partial list of overexpressed
proteins detected in lectin affinity methods. Among them
haptoglobin [31], alpha-2-microglobulin [32], tenascin C
[33], transferrin [34, 35], fibronectin [36], caveolin 1 [37,
38], heat shock 70 kDa protein 5 [39], and ceruloplasmin
[40] have been reported to be upregulated in HCC. We also
found several interesting proteins, which are highly over-
expressed and they have not been reported in HCC. These
include serpin peptidase inhibitor (clade A, member 3),
alpha-2-HS-glycoprotein, calumenin, cysteine and glycine-
rich protein 1, beta-galactoside-binding lectin, peroxire-
doxin 2, and clusterin isoform 2. Similarly, many of the
proteins enriched by lectin affinity have been shown to be
associated with HCC, demonstrating effectiveness of our
approach. Lectin affinity method enriched several known
glycosylated proteins. Galectin 1 is one such protein
overexpressed (3.0-fold) in HCC, which has been reported
to be overexpressed at mRNA level in HCC [41]. Alpha-2-
glycoprotein 1, zinc and alpha 1B-glycoprotein were found
to be 5.0 and 3.1-fold overexpressed in HCC, respectively.
Many studies on cancer-associated glycosylation reported
upregulated proteins such as haptoglobin related protein
and hemopexin which are known to undergo glycosylation
in HCC [42, 43]. Clusterin isoform 2 (apolipoprotein J), a
sulfated glycoprotein involved in apoptosis, cell death and
complement activation, was found to be five-fold upregu-
lated in the present study. Clusterin is a known potential
biomarker involved in HCC metastasis [44–46]. Similarly, a
glycated form of haptoglobin (>15-fold in HCC) has been
shown to be elevated in sera from an HCC patient [31],
indicating that quantitative proteomics coupled to lectin
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affinity method is a promising strategy for cancer biomark-
er study.
Figure 2 (panels A, B, and C) shows some of the MS
and MS/MS spectra of proteins respectively, fetuin, destrin
and SERPINA1, which were detected only in lectin affinity
enrichment method. Fetuin is a serum glycoprotein, which
has earlier been shown to contain both N-glycans and O-
glycans [47, 48]. SERPINA1 has been shown to contain N-
glycans and mass-spectrometry-based quantitation was
successfully used for the measurements of extent of
glycosylation [49]. Figure 3 shows the MS and MS/MS
spectra of peptides derived proteins, which were also found
in whole proteome analysis. MS spectra of peptides from
hemopexin (panel A) and peptidylprolyl isomerase B
(PPIB; panel B) show increase in glycosylated form when
compared to MS spectra from whole proteome analysis.
Hemopexin has been found to contain many N-glycan and
O-glycan sites [50]. Interestingly, PPIB is not known to be
glycosylated; however, in the present study, we observe an
elevated glycosylated form in tumor tissue. Similarly,
transgelin and cofilin 1 (Fig. 4, panels A and B) indicate
different levels of glycosylation in cancer and normal
tissues. Although, further studies are necessary to validate
our approach, results indicate it is a promising method to
study cancer-specific glycosylation versus normal glyco-
sylation events. All proteins identified in lectin affinity
method need not represent the cancer-associated hyper-
glycosylation. In fact, in this study, glycosylation of CSRP1
and peroxiredoxin 6 (Fig. 5, panels A and B) shows no
change or decreased level in tumor tissue compared to
normal, respectively. In case of tenascin C and HSP
27 kDa, the known upregulated proteins associated with
HCC show an HCC-associated increase in both protein
level and glycosylated form as shown in Fig. 6 panels A
and B, respectively. In general, increased fold changes seen
in lectin affinity enrichment method indicate that transgelin,
cofilin 1, tenascin C and HSP 27 are upregulated compared
to normal tissue, whereas glycated form of CSRP1 did not
alter in tumor, glycated form of peroxiredoxin 6 seems to
downregulated in tumor compared to normal. Complete
lists of proteins identified with their relative quantitation
from the two large-scale experiments involving whole
lysates and lectin-affinity-enriched proteins from tumor
and non-tumor are given in Supplementary Tables 1 and 2,
respectively. We further analyzed the overexpressed pro-
teins identified in lectin affinity method for functional
annotations [51]. Among the 120 overexpressed proteins,
40 proteins (33%) localized to the extracellular region, 49
(40%) of proteins contain predicted or assigned signal
peptide and 25 (20%) were plasma proteins. Our data
indicate marked enrichment of glycoproteins (40%) and
membrane-related proteins (20%) which would otherwise
be under represented in the whole proteome analysis.
Novel HCC-associated Proteins Identified by Lectin
Affinity Method
Fetuin (also called as alpha-2-HS-glycoprotein) is a
glycoprotein present in serum, which is synthesized by
hepatocytes and forms dimers. Although its exact function
is unknown, it has been postulated to play a role in tissue
growth and brain development. It is found to be a
circulating inhibitor of vascular calcification [52]. Fetuin
has been shown to be associated with head and neck
cancers [53]. In our study, fetuin was overexpressed 3.8-
fold in HCC. Alpha-2-glycoprotein 1, zinc-binding (ZAG)
is a glycoprotein which has 18.2% carbohydrate and binds
zinc ions. It is a secreted protein which stimulates lipid
degradation in adipocytes [54]. ZAG is not only expressed
in normal liver and breast but also reported to be expressed
in breast cancer [55, 56], prostate cancer [57, 58], and
bladder cancer [58]. In our study, alpha-2 glycoprotein 1
Table 1 A partial list of identified proteins previously reported to be overexpressed in HCC
RefSeq accession number Gene symbol Protein name 18O/16O ratio (tumor/non-tumor) References
NP_002151.1 TNC Tenascin C 8.5 [33]
NP_997639.1 FN1 Fibronectin 1 3.5 [36]
NP_000087.1 CP Ceruloplasmin 2.4 [40]
NP_001017963.1 HSP90A1 Heat shock protein 90 kDa alpha 3.0 [39]
NP_005134.1 HP Haptoglobin 15 [31]
NP_976084.1 CLU Clusterin isoform 2 5.1 [45, 46]
NP_001002029.1 C4B Complement component 4B 5.6 [68]
NP_003093.1 SOD3 Superoxide dismutase 3, extracellular 6.6 [69]
NP_000030.1 APOA1 Apolipoprotein A-I 7.1 [70]
NP_001744.2 CAV1 Caveolin 1 4.2 [37, 38]
NP_001653.1 ARF5 ADP-ribosylation factor 5 4.3 [71]
NP_005498.1 CFL1 Cofilin 1 (non-muscle) 6.7 [72]
NP_002296.1 LGALS1 Galectin 1 2.8 [41]
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zinc was overexpressed 4.6-fold in HCC. Transgelin is an
actin cross-linking protein found in fibroblasts and smooth
muscles. Downregulation of transgelin expression in many
cell lines may be a sensitive marker for the onset of
transformation. It is reported to be overexpressed in breast
cancer, cervical cancer, colorectal cancer, endometrial
cancer, head and neck cancer, malignant lymphoma,
ovarian cancer, pancreatic cancer, prostate cancer, skin
cancer, stomach cancer, and urothelial cancer [59]. Trans-
gelin is reported to be an inhibitor of ARA54-enhanced
androgen receptor transactivation which gives an insight
into the suppressor role of transgelin in prostate cancer
Table 2 Partial list of proteins overexpressed in HCC
RefSeq accession
number




NP_005498.1 CFL1 Cofilin 1 (non-muscle) 13* 3.2
NP_000604.1 HPX Hemopexin 12* 3.7
NP_066953.1 PPIA Cyclophilin A 12 1.4
NP_003509.1 HIST1H2BG H2B histone family, member A 9.3* 0.9
NP_006477.2 FBLN1 Fibulin 1 isoform D 7.8* NF
NP_000349.1 TGFBI Transforming growth factor, beta-induced, 68 kDa 7.5* 5.1
NP_000030.1 APOA1 Apolipoprotein A-I 7.1 3.8
NP_003093.1 SOD3 Superoxide dismutase 3, extracellular 6.6 NF
NP_000005.2 A2M Alpha-2-macroglobulin 6.5 2.7
NP_006861.1 DSTN Destrin isoform A 6.5* NF
NP_003177.2 TAGLN Transgelin 6.0* 4
NP_008949.4 CEP110 Centrosomal protein 110 kDa 6.0 NF
NP_001076.2 SERPINA3 Serpin peptidase inhibitor, clade A, 5.6* 5.1
NP_003364.1 VCL Vinculin 5.6* 2.8
NP_001054.1 TF Transferrin 5.6 3.5
NP_001002029.1 C4B Complement component 4B 5.6 2.5
NP_005727.1 ACTR1A ARP1 actin-related protein 1 homolog A, centractin 5.6 NF
NP_006491.2 MCAM Melanoma cell adhesion 5.3 NF
NP_997639.1 FN1 Fibronectin 1 isoform 6 5.2 5.8
NP_976084.1 CLU Clusterin isoform 2 5.1 NF
NP_001701.2 CFB Complement factor B 5.0 NF
NP_001613.1 AHSG Fetuin 5.0* NF
NP_443204.1 LRG1 Leucine-rich alpha-2-glycoprotein 1 4.7* NF
NP_001176.1 AZGP1 Alpha-2-glycoprotein 1, zinc 4.6* NF
NP_000497.1 F2 Coagulation factor II 4.5 NF
NP_005520.3 HSPG2 Heparan sulfate proteoglycan 2 4.3* NF
NP_001653.1 ARF5 ADP-ribosylation factor 5 4.3 0.8
NP_001744.2 CAV1 Caveolin 1 4.2 6.7
NP_005338.1 HSPA5 Heat shock 70 kDa protein 5 4.0 1.5
NP_001210.1 CALU Calumenin 3.8 NF
NP_001649.1 ARF1 ADP-ribosylation factor 1 3.8 0.7
NP_937895.1 GSN Gelsolin isoform b 3.5 4.4
NP_031381.2 HSP90AB1 Heat shock 90 kDa protein 1, beta 3.3 2.2
NP_001124.1 AFM Afamin 3.2* NF
NP_002281.1 LAMA4 Laminin, alpha 4 3.2 6.9
NP_000087.1 CP Ceruloplasmin 3.2 NF
NP_570602.2 A1BG Alpha 1B-glycoprotein 3.1 4.9
NP_002209.2 ITIH4 Inter-alpha (globulin) inhibitor H4 3.0 NF
NP_001035166.1 IGHG1 Anti-RhD monoclonal T125 gamma1 heavy chain 2.9 1.7
NP_002296.1 LGALS1 Beta-galactoside-binding lectin (Galectin 1) 2.8 NF
NP_008977.1 EMILIN1 Elastin microfibril interfacer 1 2.7 NF
NP_004069.1 CSRP1 Cysteine-rich protein 1 1.1* 2.9
Fold change in the proteins detected in lectin enrichment method is compared with total protein level wherever available. Novel HCC-associated
proteins detected in this study are highlighted with an asterisk.
NF Not found
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cell growth [60]. In our study, transgelin was overex-
pressed 6.0-fold in HCC when compared to 2.5 in
whole liver proteome without lectin affinity purification.
Destrin belongs to F-actin polymerizing factor family. It
is ubiquitously expressed and reported to be associated with
colon cancer [61] and Alzheimer’s disease [62]. Destrin is
overexpressed 6.5-fold in HCC with lectin affinity
purification. Leucine-rich alpha-2 glycoprotein 1 belongs
to a leucine-rich family of proteins which are involved
in protein–protein interactions and signal transduction.
This protein consists of a single polypeptide chain with
one galactosamine and four glucosamine oligosacchar-
ides attached. Leucine-rich alpha-2 glycoprotein 1 is
reported to be a marker involved in neutrophilic granulo-
cyte differentiation [63]. It is also shown to be overex-
pressed in several cancers similar to transgelin [59]. In
our study, leucine-rich alpha-2 glycoprotein 1 was over-
expressed 4.7-fold with lectin affinity purification. Hep-
aran sulfate proteoglycan 2 or perlecan is a major
component of basement membrane and has angiogenic
and growth-promoting attributes. It acts as a co-receptor
for basic fibroblasts growth factor. It is reported that
antisense targeting of perlecan subsides tumor growth and
angiogenesis, and could be a potential target for therapeu-
tics [64]; it has been shown to be overexpressed in
prostate cancer [65]. In our study, perlecan was overex-
pressed 4.3-fold in HCC with lectin affinity enrichment.
Hemopexin is a heme-binding plasma glycoprotein which
is synthesized in liver and forms about 1.4% of total serum
proteins. Each molecule of hemopexin binds to one heme
and transports it to hepatocytes for salvage of the iron; it
plays an important in receptor mediated cellular uptake of
heme [66]. It has been reported that expression of
hemopexin is low in fetal liver and its expression increases
in adult liver [67]. In our study, hemopexin was overex-
pressed threefold in HCC.
Fig. 2 Differential proteomic analysis by 18O labeling: Proteins
identified only in lectin affinity enrichment. Panel of MS spectra and
MS/MS spectra showing fold changes and peptide sequence identifi-
cation from overexpressed proteins in HCC. Panels A, B, and C show
the MS and MS/MS spectra of HTLNQIDEVK (fetuin), YALYDAS-
FETK (destrin) and ADLSGITGAR (SERPINA1), respectively. The
fold changes after lectin affinity enrichment is indicated in MS spectra
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Fig. 3 Quantitative analysis of protein changes by whole proteome
and lectin enrichment analysis. Panels A and B show the MS and MS/
MS spectra of GGYTLVSGYPK (hemopexin) and TVDNFVALATGEK
(peptidylprolyl isomerase B), respectively. The fold changes at the
whole proteome level and after lectin affinity enrichment are indicated
in MS spectra
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Validation of CSRP1 and Fetuin Western Blot and IHC
Validation of proteomic data is crucial for eliminating
the artifacts of sample heterogeneity. Western blotting
and immunohistochemical labeling methods were used
for confirming and validating the expression level in
tissue microarrays. Based on the availability of anti-
bodies, we checked the expression levels of cysteine
and glycine-rich protein (CSRP 1) and fetuin in HCC
and adjacent normal tissue and found that these two
proteins were overexpressed in HCC when compared to
adjacent normal in correlation to our mass spectrometry
Fig. 4 Quantitative analysis of protein changes by whole proteome
and lectin enrichment analysis. Panel A and B show the MS and MS/
MS spectra of TLMALGSLAVTK (transgelin) and YALYDATYETK
(cofilin 1), respectively. The fold changes at the whole proteome level
and after lectin affinity enrichment are indicated in MS spectra
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data. Western blot results shown in Fig. 7a indicates
upregulation of CSRP 1 and fetuin from whole proteome.
However, as observed in 18O-labeling analysis after
lectin enrichment, Western blot shows no change in
CSRP1 and increase in level of fetuin in HCC. Fig. 7b
shows the increased staining CSRP 1 and fetuin in tumor
tissue compared to non-tumor tissue used for proteomic
analysis.
Fig. 5 Quantitative analysis of protein changes by whole proteome
and lectin enrichment analysis. Panels A and B show the MS and MS/
MS spectra of GLESTTLADK (CSRP 1) and LSILYPATTGR (perox-
iredoxin 6), respectively. The fold changes at the whole proteome
level and after lectin affinity enrichment are indicated in MS spectra
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Validation of Fetuin as an Overexpressed Protein in HCC
Using Tissue Microarrays
We used a total of 114 tissue samples from liver cancer
patients and 79 non-cancerous liver tissues for the
validation of fetuin expression using immunohistochemical
labeling. Tumor tissues were grouped into grade I (21
cases), grade II (47 cases), grade III (28 cases), grade IV
(five cases), and 13 metastasis tissues. The scoring of the
TMAs was done by an expert pathologist, in which the
Fig. 6 Quantitative analysis of protein changes by whole proteome
and lectin enrichment analysis. Panels A and B show the MS and MS/
MS spectra of ETFTTGLDAPR (tenascin C) and QLSSGVSEIR (HSP
27-kDa), respectively. The fold changes at the whole proteome level
and after lectin affinity enrichment are indicated in MS spectra
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intensity and distribution were each scored from 0 to 3
points. Although fetuin was detectable in both non-cancer
and HCC sections, the overall intensity and distribution of
staining pattern indicates that fetuin overexpression in HCC
compared non-cancer tissues (Fig. 8). No significant
difference in expression levels of fetuin among different
tissue grades was found. TMAs obtained from a different
commercial source contained 32 non-neoplastic matching
tissues among them 28 samples showed increased distribu-
tion of staining for fetuin compared to matching non-cancer
tissues (p<0.05). In all, fetuin was overexpressed in 60/114
(52%) of HCC cases with the total score ranging from 2 to
5 whereas in non-HCC cases, 27/79 (34%) showed
expression of fetuin with total score less than 2.
Identification of N-glycosylation Sites
Using PNGase F and 18O-water, we identified 34 N-
glycosylation sites from 28 HCC-associated proteins. The
peptides containing the N-glycosylation sites are presented
in Table 3, which also shows the consensus sequences
identified for each peptide, Mascot score and expect values.
*N-X-T/S motif indicates cleavage of glycosylated group at
aspargine, incorporation of an 18O atom, and conversion of
Asn to Asp 18O (+3 Da). PNGase F cleaves innermost
GlcNAc residue linked to Asn resulting in deamidation of
Asn to Asp. Earlier, Kristiansen et al. used PNGase F and 18O-
water successfully for the identification of N-glycosylated
proteins in human bile [20]. Sites identified using PNGaseF
treatment contain N-X-T/S motif. Comparison of these sites
with the well-annotated human protein database (www.hprd.
org) showed majority of known glycosylation sites which
indicate glycopeptide enrichment using lectin affinity meth-
od, indeed an efficient approach for the enrichment of
subproteome. We also identified 14 novel N-glycosylation
sites from 12 HCC-associated proteins, two of the novel N-
linked glycosylation sites are annotated in MS/MS spectrum
as shown in Fig. 9.
Levels of Transgelin and Destrin in Lectin-enriched Serum
To evaluate the expression of some of the interesting
candidate proteins found in our study, we used lectin affinity
enrichment of serum for Western blot analysis to see whether
tissue-level fold change is reflected in the serum from HCC
patients. In this experiment, sera from eight HCC patients
and pooled normal sera (Invitrogen) were chosen for lectin
affinity enrichment followed by Western blot analysis.
Figure 10 shows an average increase level of transgelin
and destrin in serum of HCC compared to normal.
Fig. 7 Validation of fetuin and
cysteine-rich protein by Western
blotting and immunohistochem-
ical labeling in tissues used for
proteomic analysis. A The
homogenates from the tissue
samples were resolved by SDS-
PAGE and subsequently elec-
troblotted onto nitrocellulose
membrane and probed with
specific antibodies as indicated.
B Shows immunohistochemical
labeling for fetuin and CSRP1,
respectively
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Conclusions
Quantitative profiling of proteins in HCC revealed many
overexpressed proteins relevant to HCC. Many proteins that
have been previously associated with HCC were detected in
this study. Important among those were complement
component H, tenascin C, ceruloplasmin, haptoglobin, and
alpha-2 macroglobin. More importantly, a number of novel
HCC-associated proteins discovered in this study are
candidates for validation in HCC using alternate platforms
such as immunohistochemical labeling or ELISA. One of
the novel candidates, fetuin was validated as a potential
biomarker using tissue microarrays containing 114 tumor
and 79 normal liver tissue sections. Although many lectin-
bound proteins were found to be overexpressed in HCC,
whole protein levels were also high in both normal and
tumor cells. We also compared the extent of fold changes in
proteins before and after lectin affinity enrichment to
evaluate the status of glycosylation in HCC. Many of the
proteins identified in this study showed differences in fold
changes before and after lectin affinity enrichment indicat-
ing that this subset of proteins may represent hyper-
glycosylation associated with cancer. This approach is
useful in identifying cancer-associated proteins which are
Fig. 8 Immunohistochemical
labeling for alpha-2HS-
glycoprotein proteins in tissue
microarrays. Six representative
sections from tissue microarrays
(TMAs) containing 114 tumor
and 79 normal tissues are shown
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otherwise undetectable in a complex mixture. For example,
fetuin, SERPINA1, and destrin were identified only by
lectin affinity method because of reduced complexity.
Hemopexin, peptidyl prolyl isomerase B, cofilin 1, and
HSP 27-kDa protein showed more fold changes in lectin
affinity method indicating glycation specific changes in
these proteins in HCC. Our study showed many N-linked
glycosylation sites from HCC including novel sites, which
may be of interest for further study of glycoprotein marker.
Nearly 30% of the protein-bound lectins contain confirmed








Peptide sequence Known? Consensus
motif
NP_000005.2 Alpha-2-macroglobulin 1.0E−01 42 SLGNV*NFTVSAEALESQELCGTEVPSVPEHGRK YES NFT
2.1E−03 57 VS*NQTLSLFFTVLQDVPVR YES NQT
NP_000375 Apolipoprotein B 8.3E−05 62 F*NSSYLQGTNQITGR YES NSS
NP_001638.1 Apolipoprotein D 7.2E−02 42 ADGTVNQIEGEATPV*NLTEPAKLEVK YES NLT
P00450 Ceruloplasmin 3.4E−06 85 E*NLTAPGSDSAVFFEQGTTR YES NLT
NP_001822.2 Clusterin isoform 1 2.1E−05 76 LA*NLTQGEDQYYLR YES NLT
NP_009224.2 Complement component 4A 1.3E−02 47 GL*NVTLSSTGR NO NVT
NP_001747.2 Corticosteroid binding
globulin
3.4E−04 54 AQLLQGLGF*NLTER YES NLT
NP_005132.2 Fibrinogen, beta chain 9.5E−05 59 GTAGNALMDGASQLMGE*NR(T) NO NRT
NP_000500.2 Fibrinogen, gamma chain
isoform gamma-A
1.5E−06 78 DLQSLEDILHQVE*NK(T) YES NKT
NP_006673.1 Fibrinogen-like 2 9.9E−02 38 LDGST*NFTR NO NFT
7.1E−05 62 LHVGNY*NGTAGDALR NO NGT
NP_997640.1 Fibronectin 1 isoform 2 4.3E−02 44 DQCIVDDITYNV*NDTFHK YES NDT
NP_997640 Fibronectin 1 isoform 2 8.9E−07 82 LDAPTNLQFV*NETDSTVLVR NO NET
NP_009201 FK506 binding protein 9 1.1E−03 51 YHYNASLLDGTLLDSTWNLGK NO NAS
NP_005657.1 H factor (complement)-like 3 6.5E−05 61 LQNNEN*NISCVER NO NIS
NP_005134 Haptoglobin 1.5E−05 78 MVSHH*NLTTGATLINEQWLLTTAK YES NLT
3.5E−07 85 NLFL*NHSENATAK YES NHS
2.9E−06 71 VVLHP*NYSQVDIGLIK YES NYS
NP_000604 Hemopexin 2.1E−05 76 ALPQPQ*NVTSLLGCTH YES NVT
3.5E−08 94 SWPAVG*NCSSALR YES NCS
NP_000403.1 Histidine-rich glycoprotein 5.6E−03 52 VIDF*NCTTSSVSSALANTK YES NCT
NP_002207 Inter-alpha globulin inhibitor
H2
2.3E−02 37 GAFISNFSMTVDGK YES NFS
NP_000884 Kininogen 1 isoform 2 5.4E−06 73 ITYSIVQTNCSK NO NCS
NP_071751 Leucine proline-enriched
proteoglycan 1
2.7E−03 47 VPLQSAHLYYNVTEK NO NVT
NP_006491 Melanoma cell adhesion
molecule
7.2E−03 42 CVASVPSIPGLNR(T) NO NRT
NP_002395 Microfibrillar-associated
protein 4
2.3E−04 57 FNGSVSFFR NO NGS
1.1E−04 69 VDLEDFE*NNTAYAK NO NNT
NP_006380.1 Oxygen regulated protein 3.2E−09 104 LSALDNLL*NHSSMFLK YES NHS
CAJ15161 Alpha-antitrypsin 4.0E−08 102 YLG*NATAIFFLPDEGK YES NAT
NP_000479.1 Serine (or cysteine)
proteinase inhibitor, clade C
8.1E−06 70 LGAC*NDTLQQLMEVFK YES NDT
NP_001076.2 serpin peptidase inhibitor,
clade A
2.3E−04 65 F*NLTETSEAEIHQSFQHLLR NO NLT
NP_001031.2 Sex hormone-binding
globulin
9.5E−03 41 LDVDQAL*NR(S) NO NRS
NP_001054 Transferrin 7.4E−06 72 CGLVPVLAENY*NK(S) YES NKS
3.0E−02 46 QQQHLFGS*NVTDCSGNFCLFR YES NVT
Accession number and protein names were from NCBI RefSeq database, and mascot score and expect values were listed for N-glycosylated
peptides. Human protein reference database (www.hprd.org) was used for the identification of previously reported N-glycosylation sites. An
asterisk in *N-X-T/S implies 18 O labeling of Asn after PNGase F mediated cleavage of glycan.
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Fig. 9 MS/MS spectra of peptides from fibrinogen-like 2 and
complement component 4A analyzed using QToF. The spectra A
and B show the N-glycosylation sites of the peptide LDGST*NFTR
from fibrinogen-like 2 and GL*NVTLSSTGR from complement
component 4A respectively (where *N indicates the N-glycosylation
site modified by 18O). Spectrum shows the conversion of Asn to Asp
after PNGase F treatment
Fig. 10 Validation of candidate proteins by Western blotting in
serum. Serum samples (7 mg) from HCC patients and normal pooled
sample was enriched for glycoproteins using mixture of lectins as
explained in methods. Eluted proteins were resolved by SDS-PAGE
and subsequently electroblotted onto nitrocellulose membrane and
probed with antibodies for destrin and transgelin
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N-glycosylation sites indicating this technical approach of
quantitative proteomics using multiple lectin affinity
method can be used for simple screening of biomarkers
in cancer. Majority of the confirmed N-glycosylation sites
were found in proteins upregulated in HCC such as
haptoglobin, hemopexin, clusterin, and ceruloplasmin.
While many potential biomarker studies in HCC are
based on identification and validation of single upregu-
lated proteins which involve unfractionated serum or
tissues, lectin affinity allows enrichment of subproteomes
containing aberrantly glycated proteins and help in
identification of multiple markers in a single analysis.
A significant number of upregulated proteins (40%) identi-
fied in this study were also predicted to be N-glycosylated
proteins [51]. In our study, PNGase F treatment in the
presence of 18O-water found to be useful for the identifi-
cation of N-glycosylation sites in addition to the presence
of consensus motif N-X-T/S. In conclusion, quantitative
proteomic approach can be successfully used for the
analysis of subproteomes, such as glycosylated proteins,
to specifically identify and quantitate N-glycosylated
proteins and peptides.
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